Pulmonology

Participants described how payer requirements and documentation of steroid exposure shape biologic access.

Reena Mehra, MD, discusses a post hoc analysis in which AD109 reduced AHI4 by 59.6% in postmenopausal women vs 44.0% in non-menopausal participants.

Check out highlights from news published on day 3 of CHEST 2026, spanning COPD, pulmonary embolism, pulmonary hypertension, and AI.

At CHEST 2026, Retno Ariza Soemarwoto, MD, discusses curcumin’s effect on IL-17 in COPD, bioavailability, and what a guideline-ready trial needs.

At CHEST 2026, Jean Bourbeau, MD, said AI may support COPD diagnosis, remote monitoring, and posthospital care, though most tools still need validation.

At CHEST 2026, Pettigrew reviewed STRATIFY and STORM-PE data, citing bleeding risk with low-dose alteplase and 90-day walk gains with thrombectomy.

In an interim extension analysis presented at NACFC 2026, 37.5% of young children with CF in a PERT substudy stopped enzyme therapy on the regimen.

Day 2 highlights from Phoenix covering PE intervention trials, pulmonary hypertension diagnostics, ILD telomere biology, and more.

Samantha Pettigrew, MD, reviews HI-PEITHO, PRAGUE-26, and PEERLESS and how they shape intervention choices in intermediate-risk PE at CHEST 2026.

Anjali Vaidya, MD, explains why echocardiography should inform right heart catheterization interpretation in pulmonary hypertension at CHEST 2026.

In 503 patients with ILD, telomere length below the 10th percentile was linked to UIP pattern on CT and higher MIL-UIP scores but not greater fibrosis extent.

Omid Pourshahid, MD, MPH, discusses Medicare coverage for virtual pulmonary rehab and a matched-care pathway for center-based, hybrid, or virtual programs.

Clinicians described how steroid exposure from multiple prescribers shapes biologic decisions in asthma and COPD.

APPs described earlier recognition of type 2 disease, documentation strategies for payers, and the role of specialty pharmacy in biologic access.

Participants described how they use risk assessment, payer requirements, and patient preference to sequence PAH therapies.